ENCORAFENIB for Off label use: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 6 adverse event reports in the FDA FAERS database where ENCORAFENIB was used for Off label use.
Most Reported Side Effects for ENCORAFENIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 1,004 | 11.7% | 989 | 60 |
| Off label use | 989 | 11.6% | 165 | 186 |
| Nausea | 758 | 8.9% | 38 | 213 |
| Fatigue | 685 | 8.0% | 54 | 167 |
| Diarrhoea | 574 | 6.7% | 37 | 221 |
| Neoplasm progression | 548 | 6.4% | 163 | 107 |
| Pyrexia | 539 | 6.3% | 34 | 241 |
| Product use in unapproved indication | 506 | 5.9% | 77 | 63 |
| Vomiting | 429 | 5.0% | 24 | 173 |
| Rash | 414 | 4.8% | 22 | 83 |
| Serous retinal detachment | 297 | 3.5% | 13 | 56 |
| Arthralgia | 281 | 3.3% | 13 | 56 |
| Malaise | 266 | 3.1% | 30 | 85 |
| Decreased appetite | 261 | 3.1% | 32 | 111 |
| Asthenia | 213 | 2.5% | 29 | 85 |
Other Indications for ENCORAFENIB
Malignant melanoma (2,591)
Colon cancer (1,294)
Metastatic malignant melanoma (865)
Colorectal cancer metastatic (362)
Colorectal cancer (289)
Product used for unknown indication (241)
Neoplasm malignant (199)
Metastasis (168)
Colon cancer metastatic (134)
Thyroid cancer (115)
Other Drugs Used for Off label use
LENALIDOMIDE (5,767)
ECULIZUMAB (3,550)
CERTOLIZUMAB PEGOL (2,256)
ABOBOTULINUMTOXINA (2,170)
LEVETIRACETAM (2,161)
APREMILAST (1,995)
PROPRANOLOL (1,576)
CETIRIZINE (1,416)
HUMAN IMMUNOGLOBULIN G (1,129)
THALIDOMIDE (1,033)